Stay updated with breaking news from Guy Witberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Should myocarditis be a concern as mRNA-based COVID-19 vaccines are authorized in ever-younger age groups? The rare complication's epidemiology and insights about its mechanism hold clues.
The estimated incidence of myocarditis among patients that have received at least one dose of the Pfizer-BioNTech (BNT162b2) mRNA vaccine against coronavirus disease 2019 (COVID-19) was 2.13 cases per 100,000 persons, primarily affecting young men and presenting mostly as mild or moderate illness, as demonstrated by a recent study published in the New England Journal of Medicine.
With new insights, they still suggest myocarditis linked to the two mRNA SARS-CoV-2 vaccines is rare, usually mild and self-limited, and a lot less likely than the usually more severe cases seen in COVID-19.
Data from 2.5 million who got vaccine finds phenomenon afflicted only 0.002%, and was found to be serious in only 2% of those cases that did develop
The trio of studies found that young men appear to have higher risk.